Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
Business Of Biotech
00:00
SLK: The Next Technology After the All Impacting Antibodies
I really realized that we're the years that there were many, many assets out there that were oftentimes being deprioritized. What was interesting about SLK is that it was also a very unique and innovative asset. So here we are, this is kind of the next technology after the all impacting antibodies. And as I said, inflammation is just an area with enormous and met need. It's like, Hey, we really have a winning a winning M away here.
Transcript
Play full episode
